AFA
CYT

Alta Fundamental Advisers’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Alta Fundamental Advisers’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-117,346
Closed -$333K – 21
2023
Q3 		$333K Buy
+117,346
New +$323K 0.16% 17

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return

Alta Fundamental Advisers's CYT Position: Q4 2023 in Review

Alta Fundamental Advisers sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q4 2023, closing a stake of 117,346 shares — an estimated $333K sold.

Alta Fundamental Advisers first reported a position in CYT in Q3 2023 and held it in 1 quarter. The position peaked at $333K in Q3 2023. 38 funds tracked by Wall St. Rank hold CYT as of Q4 2023.

  • Alta Fundamental Advisers reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Alta Fundamental Advisers sold 117,346 Cyteir Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $333K.
  • Alta Fundamental Advisers first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
  • Alta Fundamental Advisers's Cyteir Therapeutics, Inc. Common Stock position peaked at $333K in Q3 2023.
  • 38 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Alta Fundamental Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.